IONIS PHARMACEUTICALS INC's ticker is IONS and the CUSIP is 462222100. A total of 363 filers reported holding IONIS PHARMACEUTICALS INC in Q1 2020. The put-call ratio across all filers is 1.31 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $28,475,838 | +12.6% | 597,479 | +2.4% | 0.01% | 0.0% |
Q1 2024 | $25,298,581 | -22.0% | 583,589 | -9.0% | 0.01% | -28.6% |
Q4 2023 | $32,431,389 | +14.0% | 641,063 | +2.2% | 0.01% | +16.7% |
Q3 2023 | $28,447,917 | +24.3% | 627,159 | +12.4% | 0.01% | +20.0% |
Q2 2023 | $22,884,647 | +13.1% | 557,754 | -1.5% | 0.01% | +25.0% |
Q1 2023 | $20,232,234 | -6.6% | 566,095 | -1.3% | 0.00% | -20.0% |
Q4 2022 | $21,672,351 | -15.4% | 573,798 | -1.0% | 0.01% | -16.7% |
Q3 2022 | $25,629,000 | +4.1% | 579,413 | -12.9% | 0.01% | 0.0% |
Q2 2022 | $24,630,000 | +21.1% | 665,316 | +21.1% | 0.01% | +50.0% |
Q1 2022 | $20,346,000 | +20.1% | 549,247 | -1.3% | 0.00% | +33.3% |
Q4 2021 | $16,937,000 | -9.9% | 556,577 | -0.7% | 0.00% | -25.0% |
Q3 2021 | $18,801,000 | -12.8% | 560,566 | +3.7% | 0.00% | 0.0% |
Q2 2021 | $21,562,000 | -12.0% | 540,529 | -0.8% | 0.00% | -20.0% |
Q1 2021 | $24,507,000 | -24.0% | 545,098 | -4.4% | 0.01% | -28.6% |
Q4 2020 | $32,227,000 | +24.1% | 569,994 | +4.1% | 0.01% | +16.7% |
Q3 2020 | $25,972,000 | -20.6% | 547,356 | -1.4% | 0.01% | -33.3% |
Q2 2020 | $32,726,000 | +25.0% | 555,061 | +0.2% | 0.01% | 0.0% |
Q1 2020 | $26,191,000 | -24.4% | 553,970 | -3.5% | 0.01% | 0.0% |
Q4 2019 | $34,661,000 | +5.7% | 573,774 | +4.8% | 0.01% | 0.0% |
Q3 2019 | $32,786,000 | -6.5% | 547,235 | +0.3% | 0.01% | -10.0% |
Q2 2019 | $35,055,000 | -16.8% | 545,435 | +5.1% | 0.01% | -16.7% |
Q1 2019 | $42,131,000 | +47.0% | 519,057 | -2.1% | 0.01% | +33.3% |
Q4 2018 | $28,667,000 | +5.3% | 530,282 | +0.5% | 0.01% | +28.6% |
Q3 2018 | $27,229,000 | +25.9% | 527,902 | +1.7% | 0.01% | +16.7% |
Q2 2018 | $21,634,000 | -9.5% | 519,161 | -4.3% | 0.01% | -14.3% |
Q1 2018 | $23,902,000 | -12.1% | 542,247 | +0.3% | 0.01% | 0.0% |
Q4 2017 | $27,206,000 | -0.5% | 540,877 | +0.3% | 0.01% | -12.5% |
Q3 2017 | $27,349,000 | +1.8% | 539,447 | +2.2% | 0.01% | 0.0% |
Q2 2017 | $26,859,000 | +26.1% | 528,000 | -0.3% | 0.01% | +33.3% |
Q1 2017 | $21,292,000 | -14.2% | 529,657 | +2.1% | 0.01% | -14.3% |
Q4 2016 | $24,809,000 | +38.8% | 518,690 | +6.3% | 0.01% | +40.0% |
Q3 2016 | $17,875,000 | +36.6% | 487,869 | -13.2% | 0.01% | +25.0% |
Q2 2016 | $13,085,000 | -42.8% | 561,835 | -0.6% | 0.00% | -42.9% |
Q1 2016 | $22,890,000 | -33.9% | 565,171 | +1.1% | 0.01% | -30.0% |
Q4 2015 | $34,618,000 | – | 559,000 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Sicart Associates LLC | 367,360 | $14,768,000 | 10.67% |
BB BIOTECH AG | 7,461,295 | $299,944,000 | 9.81% |
TANAKA CAPITAL MANAGEMENT INC | 83,399 | $3,353,000 | 7.39% |
DOWLING & YAHNKE LLC | 675,843 | $27,169,000 | 2.89% |
Opus Point Partners Management, LLC | 78,900 | $3,172,000 | 2.35% |
Motley Fool Asset Management LLC | 259,000 | $10,412,000 | 2.25% |
ARK Investment Management | 127,563 | $5,128,000 | 1.48% |
Motley Fool Wealth Management, LLC | 325,965 | $13,104,000 | 1.26% |
PINNACLE ASSOCIATES LTD | 1,514,710 | $60,891,000 | 1.16% |
Bellevue Group AG | 205,253 | $8,251,000 | 1.10% |